Bayer, Regeneron commence EYLEA Phase 3 clinical trial for wet AMD in China

Download PDF Copy

Editorial Checklist

Reviewed

Nov 28 2011Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that they have initiated a Phase 3 clinical trial evaluating the efficacy and safety of EYLEA™ (aflibercept) Injection in the neovascular form of age-related macular degeneration (wet AMD) in China.

The new trial, named SIGHT, will include approximately 300 patients and will be the largest retinal trial conducted in China. SIGHT is being led by Bayer.

"Currently, only photodynamic therapy with verteporfin is approved as a treatment for wet AMD in China, and it is only approved for the subpopulation of patients with predominantly classic wet AMD," said Kemal Malik, M.D., Head of Global Development and member of the Bayer HealthCare Executive Committee. "After reporting positive data from our large VIEW program in wet AMD, we look forward to potentially bringing this new treatment to patients with wet AMD in China."

Source:

Regeneron Pharmaceuticals, Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: Age-Related Macular Degeneration, Angiogenesis, Arthritis, Blindness, Cancer, Cataract, Cholesterol, Clinical Trial, Edema, Efficacy, Healthcare, Hypersensitivity, Macular Degeneration, Nutrition, Pain, Pharmaceuticals, Photodynamic Therapy, Protein, Rheumatoid Arthritis, Stroke, VEGF

Comments (0)

Download PDF Copy

Suggested Reading

Reduction of prenatal depression associated with higher full-term birth rates

Reduction of prenatal depression associated with higher full-term birth rates

Clinical trial shows CRISPR gene editing has exciting potential to treat a rare form of blindness

Clinical trial shows CRISPR gene editing has exciting potential to treat a rare form of blindness

Mediterranean diet and exercise reshape gut microbiome, aiding weight loss

Mediterranean diet and exercise reshape gut microbiome, aiding weight loss

Navigating the complexities of controlled release drug formulations

Navigating the complexities of controlled release drug formulations

Pioneering vaccine strategy promises to outmaneuver antimicrobial resistance

Pioneering vaccine strategy promises to outmaneuver antimicrobial resistance

Innovative CAR T cell therapy targets two proteins to combat aggressive brain tumor growth

Innovative CAR T cell therapy targets two proteins to combat aggressive brain tumor growth

Fish oil in pregnancy linked to child weight gain and metabolic risks

Fish oil in pregnancy linked to child weight gain and metabolic risks

Resistant starch diet proves a game changer for weight loss and diabetes control

Resistant starch diet proves a game changer for weight loss and diabetes control

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Korean fermented food Doenjang shows promise in alleviating menopausal symptoms